Letter: liver involvement and mortality in COVID-19 patients - authors' reply.
作者信息
Ponziani Francesca Romana, Del Zompo Fabio, Nesci Antonio, Santopaolo Francesco, Ianiro Gianluca, Gasbarrini Antonio, Pompili Maurizio
机构信息
Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Catholic University of the Sacred Heart, Rome, Italy.
出版信息
Aliment Pharmacol Ther. 2020 Oct;52(7):1264-1265. doi: 10.1111/apt.16052.
PMID:33016537
Abstract
摘要
相似文献
1
Letter: liver involvement and mortality in COVID-19 patients - authors' reply.信函：新冠病毒感染患者的肝脏受累情况及死亡率——作者回复
Aliment Pharmacol Ther. 2020 Oct;52(7):1264-1265. doi: 10.1111/apt.16052.
2
Letter: population mortality from COVID-19 and latitude-data from China. Authors' reply.信函：新冠病毒肺炎导致的人群死亡率与纬度——来自中国的数据。作者回复。
Aliment Pharmacol Ther. 2020 Oct;52(7):1261-1262. doi: 10.1111/apt.16058.
3
Letter: liver disease and COVID-19-not the perfect storm. Authors' reply".信件：肝病与2019冠状病毒病——并非完美风暴。作者回复
Aliment Pharmacol Ther. 2020 Aug;52(3):574-575. doi: 10.1111/apt.15886.
4
Letter: elevated liver enzymes and outcomes in COVID Authors' reply.信件：新冠患者中肝酶升高与预后 作者回复
Aliment Pharmacol Ther. 2020 Oct;52(7):1235-1236. doi: 10.1111/apt.16028.
5
Letter: low population mortality from COVID-19 in countries south of latitude 35° North supports vitamin D as a factor determining severity. Authors' reply.信件：北纬35°以南国家新冠病毒疾病（COVID-19）的低人口死亡率支持维生素D是决定疾病严重程度的一个因素。作者回复。
Aliment Pharmacol Ther. 2020 Jul;52(2):412-413. doi: 10.1111/apt.15823. Epub 2020 Jun 2.
6
Letter: unknown denominator and misleading conclusions in Covid-19-authors' reply.信件：关于新冠疫情中未知分母和误导性结论——作者回复
Aliment Pharmacol Ther. 2020 Oct;52(7):1243-1244. doi: 10.1111/apt.16056.
7
Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7808 patients in France. Authors' reply.
Aliment Pharmacol Ther. 2020 Oct;52(7):1249-1250. doi: 10.1111/apt.16055.
8
Letter: gastrointestinal symptoms pre-admission are associated with greater severity of COVID-19-authors' reply.信件：入院前的胃肠道症状与新冠病毒疾病的更严重程度相关——作者回复
Aliment Pharmacol Ther. 2020 Oct;52(7):1231-1232. doi: 10.1111/apt.16045.
9
Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Authors' reply.信函：肠道炎症、COVID-19与胃肠道ACE2——探索RAS抑制剂。作者回复。
Aliment Pharmacol Ther. 2020 Aug;52(3):571-572. doi: 10.1111/apt.15893. Epub 2020 Jun 25.
10
Letter: proton pump inhibitors - severity of liver disease and mortality in patients with cirrhosis - authors' reply.
Aliment Pharmacol Ther. 2015 Apr;41(7):706. doi: 10.1111/apt.13110.
Zotero 插件